Clear, aligned incentives is what limited partners want to see when investing money in a venture capital firm, says Warren Lee of Canaan Partners. Lee tells The Deal Pipeline about the impact of anemic VC fundraising on LPs. - Sarah Hashim-Waris
Three directors are leaving Valeant Pharmaceuticals International's board, including Warburg Pincus' Fred Hassan, ValueAct's G. Mason Morfit and Persistence Capital's Lloyd M. Segal. For other updates launch today's Movers & shakers slideshow.